SHASQI INC

Address: 665 3RD ST SAN FRANCISCO, CA 94107-1953
County: SAN FRANCISCO
Country: UNITED STATES
UEI: ZDH5UZ2858G3

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2026 ( Subtotal = $0 )

2026

2025

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA306491

CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry

000

NIH

11/20/2025

2026

2024

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA285160

Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry

000

NIH

1/20/2026

Issue Date FY: 2025 ( Subtotal = $1,526,048 )

2025

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA306491

CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry

000

NIH

9/24/2025

$1,094,189

2025

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA291345

Antigen-targeted activation of Topo1 inhibitors via click chemistry

000

NIH

9/12/2025

$431,859

2025

2024

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA265665

Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma

000

NIH

7/3/2025

Issue Date FY: 2024 ( Subtotal = $3,099,425 )

2024

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA291345

Antigen-targeted activation of Topo1 inhibitors via click chemistry

000

NIH

9/6/2024

$1,568,070

2024

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA265665

Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma

000

NIH

3/18/2024

$322,142

2024

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA285160

Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry

002

NIH

8/13/2024

$1,217,955

2024

2023

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA285160

Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry

001

NIH

1/16/2024

$781,732

2024

2023

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA285160

Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry

000

NIH

1/10/2024

-$781,732

2024

2022

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA261573

Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors

000

NIH

8/23/2024

-$8,742

Issue Date FY: 2023 ( Subtotal = $1,080,575 )

2023

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA265665

Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma

000

NIH

3/24/2023

$298,843

2023

SHASQI INC

665 3RD ST

SAN FRANCISCO

94107-1953

SAN FRANCISCO

USA

R44CA285160

Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry

000

NIH

9/1/2023

$781,732

Issue Date FY: 2022 ( Subtotal = $801,129 )

2022

SHASQI, INC.

665 3RD ST STE 535

SAN FRANCISCO

94107-2285

SAN FRANCISCO

USA

R44CA261573

Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors

000

NIH

4/1/2022

$801,129

2022

2021

SHASQI, INC.

665 3RD ST STE 535

SAN FRANCISCO

94107-2285

SAN FRANCISCO

USA

R44CA265665

Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma

000

NIH

9/9/2022

Issue Date FY: 2021 ( Subtotal = $2,575,634 )

2021

SHASQI, INC.

665 3RD ST STE 535

SAN FRANCISCO

94107-2285

SAN FRANCISCO

USA

R44CA261573

Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors

001

NIH

8/26/2021

2021

SHASQI, INC.

665 3RD ST STE 535

SAN FRANCISCO

94107-2285

SAN FRANCISCO

USA

R44CA261573

Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors

000

NIH

4/1/2021

$1,198,848

2021

SHASQI, INC.

665 3RD ST STE 535

SAN FRANCISCO

94107-2285

SAN FRANCISCO

USA

R44CA265665

Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma

000

NIH

9/16/2021

$1,376,786

All Categories

About

Search

Reports

Data Submission

Recipient Information

SHASQI INC

Address: 665 3RD ST SAN FRANCISCO, CA 94107-1953

County: SAN FRANCISCO

Country: UNITED STATES

UEI: ZDH5UZ2858G3

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer